After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

China on Sunday announced anti-dumping duties as high as 74.9% on imports of POM copolymers, a type of engineering plastic, ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

The FDA has approved the Novavax COVID-19 vaccine, called Nuvaxovid, mainly for adults 65 or older, but people ages 12 to 64 with medical conditions that increase their risk of serious illness from ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

(Reuters) -Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 ...

The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.

"The FDA will approve vaccines for high-risk persons and, at the same time, demand robust, gold-standard data on persons at ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental The U.S. Food and Drug Administration (FDA) ...

The agency is changing the standard of evidence required for Covid-19 vaccine approval in the US, Dr. Vinay Prasad, the new ...

T he U.S. Food and Drug Administration (FDA) will no longer recommend yearly COVID-19 vaccines for kids and most adults. In an editorial article published in the New England Journ ...